Ling‐Ming Tseng

14.3k citations
233 papers · 9.3k · 2 hit papers · h-index 44

Impact in

    • Breast Cancer Treatment Studies
    • MicroRNA in disease regulation
    • Cancer, Hypoxia, and Metabolism
  • Oncology top 0.5%
    • HER2/EGFR in Cancer Research
    • Cancer Cells and Metastasis
    • Cancer Treatment and Pharmacology

Papers in

    • HER2/EGFR in Cancer Research 31
    • Cancer Cells and Metastasis 12
    • Mitochondrial Function and Pathology 11
    • RNA modifications and cancer 11

Ling‐Ming Tseng

224 papers receiving 9.1k citations

Ling‐Ming Tseng's Hit Papers

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial 2016 · 582 citations
5820+5+10Years since publication50010001.5k

Peers

Ling‐Ming Tseng
Comparison fields: 5 of 139
  • Cancer Research 2.5k
  • Oncology 4.0k
  • Molecular Biology 3.3k
  • Radiology, Nuclear Medicine and Imaging 992
  • Pulmonary and Respiratory Medicine 1.3k
Replace Matthew P. Goetz with:
Matthew P. Goetz United States
Rebecca Dent Singapore
Francesco Cognetti Italy
Linda T. Vahdat United States
Michelino De Laurentiis Italy
Thomas Fleming Germany
C. Kent Osborne United States
Carey K. Anders United States
Epie Boven Netherlands
Rodrigo Dienstmann Spain
Ling‐Ming Tseng relative to Matthew P. Goetz United States Matthew P. Goetz's profile →
Citations per field
00.5×1.5×1.9×
Matthew P. Goetz · 1×
Citations per year

Countries citing papers authored by Ling‐Ming Tseng

Since Specialization
Citations

This map shows the geographic impact of Ling‐Ming Tseng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ling‐Ming Tseng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ling‐Ming Tseng more than expected).

Fields of papers citing papers by Ling‐Ming Tseng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ling‐Ming Tseng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ling‐Ming Tseng. The network helps show where Ling‐Ming Tseng may publish in the future.

Co-authors

The 25 scholars most cited alongside Ling‐Ming Tseng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ling‐Ming Tseng Line = papers co-authored together Ling‐Ming Tseng links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 233 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Hit paper breakdown →
20111629
2
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
Hit paper breakdown →
2016582
3 2011439
4 2009409
5 2016250
6 2017237
7 2006221
8 2007165
9 2016140
10 2012131
11 2012126
12 2011124
13 2010118
14 2010116
15 2011115
16 2012109
17 2010105
18 2023105
19 201198
20 201597

About Ling‐Ming Tseng

Ling‐Ming Tseng is a scholar working on Oncology, Molecular Biology, Cancer Research, Pulmonary and Respiratory Medicine and Genetics, having authored 233 papers that have together received 9.3k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (31 papers), Breast Cancer Treatment Studies (24 papers), Advanced Breast Cancer Therapies (24 papers), Cancer Cells and Metastasis (12 papers), Cancer Genomics and Diagnostics (12 papers), Cancer, Hypoxia, and Metabolism (12 papers), Mitochondrial Function and Pathology (11 papers) and RNA modifications and cancer (11 papers). The work is most often cited by research in Cancer Research (2.5k citations), Oncology (4.0k citations), Molecular Biology (3.3k citations), Radiology, Nuclear Medicine and Imaging (992 citations) and Pulmonary and Respiratory Medicine (1.3k citations). Ling‐Ming Tseng has collaborated with scholars based in Taiwan, United States and South Korea. Frequent co-authors include Hsin‐Chen Lee, Luca Gianni, Pinuccia Valagussa, Tadeusz Pieńkowski, Giulia Bianchi, Young‐Hyuck Im, Seock‐Ah Im, Aňa Lluch, Brigitte Poirier and Juan de la Haba-Rodríguez. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, Breast Cancer Research and Treatment, Scientific Reports and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact